Similar articles

• Dalteparin versus unfractionated heparin in critically ill patients.

  PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group; Cook D, Meade M, Guyatt G, Walter S, Heels-Ansdell D, Warkentin TE, Zytaruk N, Crowther M, Geerts W, Cooper DJ, Vallance S, Qushmaq I, Rocha M, Berwanger O, Vlahakis NE. PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group, et al. N Engl J Med. 2011 Apr 7;364(14):1305-14. doi: 10.1056/NEJMoa1014475. Epub 2011 Mar 22. N Engl J Med. 2011. PMID: 21417952 Clinical Trial.
• Dalteparin in critically ill patients.

  Smythe MA, Koerber JM. Smythe MA, et al. N Engl J Med. 2011 Jul 14;365(2):179-80; author reply 180. doi: 10.1056/NEJMc1105423. N Engl J Med. 2011. PMID: 21751919 No abstract available.
• Dalteparin and heparin-induced thrombocytopenia.

  Davidson BL. Davidson BL. N Engl J Med. 2011 Sep 22;365(12):1158; author reply 1158. doi: 10.1056/NEJMc1108392. N Engl J Med. 2011. PMID: 21992138 No abstract available.
• Risk assessment and prophylaxis of venous thromboembolism in acutely and/or critically ill patients.

  Davidson BL. Davidson BL. Haemostasis. 2000;30 Suppl 2:77-81; discussion 63. doi: 10.1159/000054168. Haemostasis. 2000. PMID: 11251346 Review.
• Prevention and treatment of thromboembolic events in medical patients and new anticoagulants.

  Balaratnam S. Balaratnam S. Acta Clin Belg. 2009 Nov-Dec;64(6):547-52. doi: 10.1179/acb.2009.093. Acta Clin Belg. 2009. PMID: 20101880 Review.